TMEM128: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Target Name: TMEM128

NCBI ID: G85013

TMEM128

TMEM128: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

TMEM128 (Tissue Membrane Expansion Module 128) is a protein that is expressed in various tissues and organs throughout the body. It is a key component of the intercellular junctions, which are vital for maintaining tissue structure and function. TMEM128 has been identified as a potential drug target and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

TMEM128 is a transmembrane protein that is expressed in the endoplasmic reticulum and cytoplasm of various cell types. It is composed of two distinct regions: an N-terminus that is involved in the formation of the intercellular junctions, and a C-terminus that is involved in the regulation of cell signaling pathways. The N-terminus of TMEM128 contains a region that is highly conserved and is involved in the formation of the intercellular junctions. This region is known as the N-end rule (NER) and is a common feature of proteins that are involved in cell signaling pathways.

The C-terminus of TMEM128 contains a region that is involved in the regulation of cell signaling pathways. This region is known as the C-end rule (CER) and is also a common feature of proteins that are involved in cell signaling pathways. The CER region of TMEM128 contains a variety of conserved motifs that are involved in the regulation of cell signaling pathways.

TMEM128 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that TMEM128 is involved in the regulation of cell signaling pathways that are involved in the development and progression of cancer. Additionally, TMEM128 has been shown to play a role in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its role in disease, TMEM128 has also been shown to be a potential drug target. Studies have shown that TMEM128 can be targeted by small molecules and antibodies, and that these treatments can inhibit the activity of TMEM128. Additionally, TMEM128 has been shown to interact with a variety of different proteins, including TGF-β1, PDGF, and NF-kappa-B. These interactions may be important for the regulation of cell signaling pathways and could be potential drug targets.

TMEM128 is also a potential biomarker for a variety of diseases. For example, studies have shown that TMEM128 levels are elevated in a variety of cancer tissues and that these levels can be used as a biomarker for the diagnosis and prognosis of cancer. Additionally, TMEM128 levels have been shown to be elevated in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and these levels can be used as a biomarker for the diagnosis and prognosis of these diseases.

In conclusion, TMEM128 is a protein that is expressed in various tissues and organs throughout the body and has been shown to play a role in the regulation of cell signaling pathways. It is also a potential drug target and has been identified as a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of TMEM128 in these diseases and to develop effective treatments.

Protein Name: Transmembrane Protein 128

The "TMEM128 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM128 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets